Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBI-101 in COVID-19 AKI
NCT04445220Phase 2Unknown
- Sponsor
- Sentien Biotechnologies
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of SBI-101 in acute kidney injury (AKI), coronavirus disease 2019 (COVID-19), sponsored by Sentien Biotechnologies. Status: unknown.
02
Drugs
SBI-101
03
Conditions
acute kidney injury (AKI)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04445220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445220.